Xenios AG – a Fresenius Medical Care company – is a pioneer in extracorporeal heart and lung support. The Novalung and Medos products offer the full range of heart and lung assist on one single platform: the Xenios console.
Xenios' dedication applies to the higher welfare of patients. The Novalung therapy can replace or supplement ventilation, which allows to prevent ventilation-associated lung damage. These minimally invasive therapies enable caregivers to keep lung failure patients awake, self-determined and mobile. End of 2016 Xenios has become part of the FME family, the worldwide market leader in renal support, and therefore forms a significant part of FME’s holistic multi-organ support.
Lung failure therapies
Novalung is the world‘s first lung failure therapy platform, which competes favorably against one-product offerings. The Novalung product family enables therapies for lung failure that are adapted to specific indications. In addition, Novalung products’ smaller cannulas lower the threshold for adoption. In short, Novalung products can replace or reduce invasive mechanical ventilation with therapies tailored to the needs of each patient. The Novalung platform performs any level of CO2 removal and oxygenation in acute respiratory failure / AECOPD.
Medos has been making German medical technology history since 1987, for the benefit of cardiac surgeons, perfusionists and patients. Whether aortic valve replacement or bypass surgery, almost all cardiac surgery procedures can be performed effectively using Medos products. Upon the acquisition of Medos by Novalung's owners the Medos blood pump technology allowed to create cardiac assist for Xenios' state-of-the-art minimally invasive therapy portfolio.
The Xenios tubing set configurator guides you through the process of creating your own individual Medos tubing